The NHS North East Treatment Advisory Group (NETAG) has issued a recommendation and associated appraisal report on use of the OmniPod® continuous subcutaneous insulin infusion pump system.

The Group does not recommend use of this technology, stating that there were concerns that differences relating to clinical and patient-orientated outcomes compared with other pump systems had not been adequately demonstrated.  I was not therefore considered to represent a cost-effective use of resources.  Patients already using OmniPod® should continue to use the system until such time that they or their clinician consider it appropriate to cease.